dbo:abstract |
فيلوسيتراج (بالإنجليزية: Velusetrag) هو دواء لعلاج الاضطرابات العصبية والعضلية المعدية،الانسداد المعوي، اضطرابات الحركة، إمساك، متلازمة القولون المتهيج. (ar) Velusetrag (INN, USAN; previously known as TD-5108) is an experimental drug candidate for the treatment of gastric neuromuscular disorders including gastroparesis, and lower gastrointestinal motility disorders including chronic idiopathic constipation and irritable bowel syndrome. It is a potent, selective, high efficacy 5-HT4 receptor serotonin agonist being developed by Theravance Biopharma and Alfa Wassermann. Velusetrag demonstrates less selectivity for other serotonin receptors, such as 5-HT2 and 5-HT3, to earlier generation 5-HT agonists like cisapride and tegaserod. In a large clinical trial in patients with chronic idiopathic constipation (n=401), velusetrag statistically and clinically improved the frequency and consistency of complete spontaneous bowel movements (CSBMs) compared to placebo. Doses of 15 and 30 mg were well tolerated compared to placebo. Velusetrag showed accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing in healthy volunteer subjects. In addition, velusetrag showed accelerated gastric emptying in patients with diabetic or idiopathic gastroparesis. The proportion of patients who experienced at least a 20% improvement is gastric emptying ranged from 20% to 52% for velusetrag dosed patients and 5% for placebo patients. On December 6, 2016, Theravance Biopharma announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to velusetrag for the treatment of symptoms associated with diabetic and idiopathic Gastroparesis. As of May 10, 2017, Velusetrag is being studied, at doses of 5, 15 and 30 mg over a 12-week treatment period, for symptomatic improvement in patients with diabetic or idiopathic gastroparesis in the DIGEST study. (en) |
dbo:casNumber |
866933-46-2 866933-51-9 (hydrochloride) |
dbo:chEMBL |
2087337 |
dbo:fdaUniiCode |
J4VNV64ARB |
dbo:kegg |
D09693 |
dbo:pubchem |
53297466 |
dbo:thumbnail |
wiki-commons:Special:FilePath/Velusetrag_structure.svg?width=300 |
dbo:wikiPageID |
32625467 (xsd:integer) |
dbo:wikiPageLength |
8660 (xsd:nonNegativeInteger) |
dbo:wikiPageRevisionID |
1085709346 (xsd:integer) |
dbo:wikiPageWikiLink |
dbr:Potency_(pharmacology) dbr:Prucalopride dbc:Motility_stimulants dbr:International_nonproprietary_name dbr:Intrinsic_activity dbc:Isopropyl_compounds dbc:Serotonin_receptor_agonists dbc:Tropanes dbr:Gastroparesis dbr:Cisapride dbr:Constipation dbr:Irritable_bowel_syndrome dbr:Agonist dbr:5-HT4_receptor dbc:2-Quinolones dbr:Tegaserod dbr:Hydrochloride dbc:Sulfonamides dbr:Binding_selectivity dbr:United_States_Adopted_Name dbr:Naronapride |
dbp:atcPrefix |
None (en) |
dbp:c |
25 (xsd:integer) |
dbp:casNumber |
866933 (xsd:integer) |
dbp:casSupplemental |
866933 (xsd:integer) |
dbp:chembl |
2087337 (xsd:integer) |
dbp:chemspiderid |
28527582 (xsd:integer) |
dbp:h |
36 (xsd:integer) |
dbp:image |
Velusetrag2.png (en) |
dbp:iupacName |
N-{-8-[-2-Hydroxy-3-propyl]-8-azabicyclo[3.2.1]octan-3-yl}-2-oxo-1--1,2-dihydroquinoline-3-carboxamide (en) |
dbp:iupharLigand |
8425 (xsd:integer) |
dbp:kegg |
D09693 (en) |
dbp:legalUs |
IND (en) |
dbp:n |
4 (xsd:integer) |
dbp:o |
5 (xsd:integer) |
dbp:pubchem |
53297466 (xsd:integer) |
dbp:routesOfAdministration |
Oral (en) |
dbp:s |
1 (xsd:integer) |
dbp:smiles |
CCN1C2=CC=CC=C2C=CCN[C@H]3C[C@H]4CC[C@@H]N4C[C@H]O (en) |
dbp:stdinchi |
1 (xsd:integer) |
dbp:stdinchikey |
HXLOHDZQBKCUCR-WOZUAGRISA-N (en) |
dbp:synonyms |
(N-[-8-{-2-Hydroxy-3-[methylamino]propyl}-8-azabicyclo[3.2.1]oct-3-yl]-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamide) (en) |
dbp:unii |
J4VNV64ARB (en) |
dbp:width |
250 (xsd:integer) |
dbp:wikiPageUsesTemplate |
dbt:Infobox_drug dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Drugs_for_functional_gastrointestinal_disorders |
dcterms:subject |
dbc:Motility_stimulants dbc:Isopropyl_compounds dbc:Serotonin_receptor_agonists dbc:Tropanes dbc:2-Quinolones dbc:Sulfonamides |
gold:hypernym |
dbr:Candidate |
rdf:type |
owl:Thing dbo:Person dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:WikicatMotilityStimulants yago:Abstraction100002137 yago:Cognition100023271 yago:Communication100033020 yago:Formula106816935 yago:Information105816287 yago:Message106598915 yago:MolecularFormula106817173 yago:PsychologicalFeature100023100 dbo:Drug yago:Statement106722453 yago:Stimulation105827684 |
rdfs:comment |
فيلوسيتراج (بالإنجليزية: Velusetrag) هو دواء لعلاج الاضطرابات العصبية والعضلية المعدية،الانسداد المعوي، اضطرابات الحركة، إمساك، متلازمة القولون المتهيج. (ar) Velusetrag (INN, USAN; previously known as TD-5108) is an experimental drug candidate for the treatment of gastric neuromuscular disorders including gastroparesis, and lower gastrointestinal motility disorders including chronic idiopathic constipation and irritable bowel syndrome. It is a potent, selective, high efficacy 5-HT4 receptor serotonin agonist being developed by Theravance Biopharma and Alfa Wassermann. Velusetrag demonstrates less selectivity for other serotonin receptors, such as 5-HT2 and 5-HT3, to earlier generation 5-HT agonists like cisapride and tegaserod. (en) |
rdfs:label |
فيلوسيتراج (ar) Velusetrag (en) |
owl:sameAs |
freebase:Velusetrag yago-res:Velusetrag wikidata:Velusetrag dbpedia-ar:Velusetrag dbpedia-sh:Velusetrag dbpedia-sr:Velusetrag https://global.dbpedia.org/id/4xppg |
prov:wasDerivedFrom |
wikipedia-en:Velusetrag?oldid=1085709346&ns=0 |
foaf:depiction |
wiki-commons:Special:FilePath/Velusetrag2.png wiki-commons:Special:FilePath/Velusetrag_structure.svg |
foaf:isPrimaryTopicOf |
wikipedia-en:Velusetrag |
is dbo:wikiPageRedirects of |
dbr:C25H36N4O5S dbr:Velusetrag_hydrochloride dbr:TD-5108 dbr:TD5108 dbr:TD_5108 |
is dbo:wikiPageWikiLink of |
dbr:Functional_constipation dbr:C25H36N4O5S dbr:List_of_drugs:_V–Ve dbr:Velusetrag_hydrochloride dbr:TD-5108 dbr:TD5108 dbr:TD_5108 |
is foaf:primaryTopic of |
wikipedia-en:Velusetrag |